An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Biote Appoints Ross W. McQuivey, M.D. as Chief Medical Officer
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Biote Corp. (Nasdaq: BTMD) has appointed Dr. Ross W. McQuivey as Chief Medical Officer, effective June 10, 2022. Dr. McQuivey brings over 20 years of experience in medical leadership, having previously served as CMO at Laborie Medical Technologies. His role will focus on driving clinical research and expanding the Biote Method in mainstream medicine. CEO Terry Weber expressed confidence in Dr. McQuivey’s experience, highlighting its alignment with Biote’s strategic growth plans in the hormone optimization sector.
Positive
Dr. McQuivey brings over 20 years of medical and scientific leadership, enhancing the executive team's expertise.
His appointment is expected to drive clinical research and broaden the Biote Method's reach.
Negative
Concerns may arise regarding the continuity and experience of the executive team as a new CMO is integrated.
Innovative physician leader brings over 20 years of experience to Biote’s executive team
IRVING, Texas--(BUSINESS WIRE)--
biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, today announced that it has appointed Ross W. McQuivey, M.D., as its Chief Medical Officer, effective June 10, 2022. Dr. McQuivey will be responsible for leading continuing clinical research efforts and publications. The Company also expects that he be instrumental in expanding the Biote Method to mainstream medicine.
Dr. McQuivey brings to Biote more than 20 years of medical and scientific leadership in the healthcare industry, with management experience in research and development, medical affairs, as well as regulatory and quality control. He has published over a dozen peer-reviewed journal articles, abstracts and poster presentations, and has lectured extensively in the United States and internationally.
Prior to joining Biote, Dr. McQuivey served as Chief Medical Officer of Laborie Medical Technologies, a global medical technology company focused on urology, urogynecology, gastroenterology, obstetrics, gynecology and neonatal health. He previously held multiple roles of increasing responsibility at Clinical Innovations, LLC, a provider of products for the labor and delivery and neonatal intensive care unit specialties, from 2003 to 2020, with his last position as Chief Medical Officer before the company was acquired. He has held various board positions, including the Journal of Clinical Obstetrics, Gynecology & Infertility, Patient Safety Movement Foundation and the National Patient Safety Council. Additionally, Dr. McQuivey is a member of the American College of Obstetrics and Gynecology (“ACOG”), the American Medical Association and the Society of Simulation in Healthcare. Previously, he was also a member of the Utah Medical Association and the Utah Section ACOG. Dr. McQuivey earned his Doctor of Medicine from the University of Utah School of Medicine and holds a Bachelor of Arts in psychology from Stanford University.
“We are thrilled to welcome Dr. Ross McQuivey to our company at an exciting time,” said Terry Weber, Chief Executive Officer of Biote. “Ross’ extensive experience overseeing clinical affairs in support of rapidly growing companies will be instrumental to the execution of our strategic growth plans.”
“It is an honor to take on this role during this transformative period for Biote,” said Dr. Ross McQuivey. “I’m delighted to work alongside a talented executive team to continue to bring attention to the hormone optimization space. As a physician, I am passionate about improving patients’ lives; I believe that Biote has the power to optimize the health of many, and I am looking forward to the opportunity to deliver on Biote’s core mission of providing a convenient solution to a broad, and often underserved patient population.”
About Biote
Biote is a woman-led company operating a high growth, differentiated medical practice-building business within the hormone optimization space. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions. Biote went public on Nasdaq on May 27, 2022. To learn more about Biote, please visit www.biote.com.
Forward Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the federal U.S. securities laws with respect our expectations regarding future growth, performance, business prospects and opportunities, future plans and intentions or other future events. These forward-looking statements generally are identified by words such as “anticipate”, “believe”, “expect”, “may”, “could”, “will”, “potential”, “intend”, “estimate”, “should”, “plan”, “predict”, or the negative or other variations of such statements, reflect our management’s current beliefs and assumptions and are based on the information currently available to our management. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the ability to implement business plans, forecasts and other expectations, and identify and realize additional opportunities; the risk of downturns in the market and Biote’s industry including, but not limited to, as a result of the COVID-19 pandemic; risks and uncertainties related to Biote’s business, including, but not limited to, those related to regulation, its supply chain, its executive influence, its limited operating history, highly competitive markets and competition, data privacy and cybersecurity, its ability to grow, its financial condition and potential dilution, its forecasts, expansion, intellectual property, current or future litigation, capital requirements and the need for additional capital, physician training, relationships with physicians, its key employees and qualified personnel, third-party manufacturers, regulatory scrutiny of the pharmacy compounding industry, health care fraud and abuse, HIPAA, and its dietary supplement business. The foregoing list of factors is not exclusive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the proxy statement and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and Biote does not assume any obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Biote does not give any assurance that it will achieve its expectations.
